PL3603619T3 - Preparat adjuwantu szczepionkowego - Google Patents
Preparat adjuwantu szczepionkowegoInfo
- Publication number
- PL3603619T3 PL3603619T3 PL18774978.3T PL18774978T PL3603619T3 PL 3603619 T3 PL3603619 T3 PL 3603619T3 PL 18774978 T PL18774978 T PL 18774978T PL 3603619 T3 PL3603619 T3 PL 3603619T3
- Authority
- PL
- Poland
- Prior art keywords
- vaccine adjuvant
- adjuvant formulation
- formulation
- vaccine
- adjuvant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017066280 | 2017-03-29 | ||
| PCT/JP2018/012637 WO2018181420A1 (ja) | 2017-03-29 | 2018-03-28 | ワクチンアジュバント製剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3603619T3 true PL3603619T3 (pl) | 2025-11-17 |
Family
ID=63675951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18774978.3T PL3603619T3 (pl) | 2017-03-29 | 2018-03-28 | Preparat adjuwantu szczepionkowego |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11253476B2 (pl) |
| EP (1) | EP3603619B1 (pl) |
| JP (1) | JP7169968B2 (pl) |
| CN (1) | CN110650729B (pl) |
| CA (1) | CA3057813A1 (pl) |
| DK (1) | DK3603619T3 (pl) |
| ES (1) | ES3039485T3 (pl) |
| FI (1) | FI3603619T3 (pl) |
| HU (1) | HUE073137T2 (pl) |
| PL (1) | PL3603619T3 (pl) |
| WO (1) | WO2018181420A1 (pl) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8778028B2 (en) | 2005-02-25 | 2014-07-15 | Shoulder Innovations, Inc. | Methods and devices for less invasive glenoid replacement |
| US20230080207A1 (en) | 2005-02-25 | 2023-03-16 | Shoulder Innovations, Inc. | Methods and devices for less invasive glenoid replacement |
| US10492926B1 (en) | 2014-09-04 | 2019-12-03 | Shoulder Innovations, Inc. | Alignment guide for humeral or femoral stem replacement prostheses |
| PL3603619T3 (pl) | 2017-03-29 | 2025-11-17 | Sumitomo Pharma Co., Ltd. | Preparat adjuwantu szczepionkowego |
| WO2018191420A1 (en) | 2017-04-14 | 2018-10-18 | Shoulder Innovations, Llc | Total shoulder prosthesis having inset glenoid implant convertible from anatomic to reverse |
| CA3107409A1 (en) | 2018-07-23 | 2020-01-30 | Japan As Represented By Director General Of National Institute Of Infectious Diseases | Composition containing influenza vaccine |
| CN113194986A (zh) * | 2018-12-26 | 2021-07-30 | 大日本住友制药株式会社 | 包括疫苗佐剂的制剂 |
| EP3936147A4 (en) * | 2019-03-04 | 2022-09-28 | JAPAN as represented by DIRECTOR GENERAL of National Institute of Infectious Diseases | METHOD OF MANUFACTURE OF AN INFLUENZA HA-SPLIT VACCINE |
| JP7691369B2 (ja) | 2019-03-11 | 2025-06-11 | ショルダー・イノベーションズ・インコーポレイテッド | 全リバースショルダーシステムおよび方法 |
| EP3949983A4 (en) * | 2019-04-05 | 2022-12-21 | Sumitomo Pharma Co., Ltd. | WATER SOLUBLE ADJUVANT |
| JP2023512204A (ja) * | 2020-01-27 | 2023-03-24 | ブリストル-マイヤーズ スクイブ カンパニー | トール様受容体7(TLR7)アゴニストとしての1H-ピラゾロ[4,3-d]ピリミジン化合物 |
| US20230131192A1 (en) * | 2020-01-27 | 2023-04-27 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| WO2025263617A1 (ja) * | 2024-06-21 | 2025-12-26 | 住友ファーマ株式会社 | コレステロールとtlr7アゴニストのコンジュゲート体およびそれを含む医薬組成物 |
| WO2026018889A1 (ja) * | 2024-07-19 | 2026-01-22 | 住友ファーマ株式会社 | ワクチンアジュバントを含むリポソーム製剤 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA848968B (en) | 1983-11-18 | 1986-06-25 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines |
| IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| ATE283855T1 (de) | 1996-07-03 | 2004-12-15 | Sumitomo Pharma | Neue purinderivate |
| NZ504800A (en) | 1997-11-28 | 2001-10-26 | Sumitomo Pharma | 6-Amino-9-benzyl-8-hydroxy-purine derivatives and interferon inducers, antiviral agents, anticancer agents and therapeutic agents for immunologic diseases thereof |
| ES2221414T3 (es) | 1998-08-27 | 2004-12-16 | Sumitomo Pharmaceuticals Company, Limited | Derivados de pirimidina. |
| JP4178632B2 (ja) | 1998-12-11 | 2008-11-12 | 和光純薬工業株式会社 | 干渉作用を回避する方法及び試薬 |
| US7157465B2 (en) | 2001-04-17 | 2007-01-02 | Dainippon Simitomo Pharma Co., Ltd. | Adenine derivatives |
| ES2389080T3 (es) | 2004-06-11 | 2012-10-23 | Riken | Fármaco que presenta un ligando de células reguladoras contenido en el liposoma |
| ZA200803029B (en) | 2005-09-09 | 2009-02-25 | Coley Pharm Group Inc | Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods |
| WO2007093901A1 (en) | 2006-02-17 | 2007-08-23 | Pfizer Limited | 3 -deazapurine derivatives as tlr7 modulators |
| US20100120799A1 (en) | 2007-02-19 | 2010-05-13 | Smithkline Beecham Corporation | Purine derivatives as immunomodulators |
| EP2132209B8 (en) | 2007-03-19 | 2014-04-16 | AstraZeneca AB | 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7 ) modulators |
| EP2139894B1 (en) | 2007-03-19 | 2011-10-26 | AstraZeneca AB | 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators |
| WO2008114819A1 (ja) | 2007-03-20 | 2008-09-25 | Dainippon Sumitomo Pharma Co., Ltd. | 新規アデニン化合物 |
| AR065784A1 (es) | 2007-03-20 | 2009-07-01 | Dainippon Sumitomo Pharma Co | Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas. |
| KR20100016289A (ko) | 2007-05-08 | 2010-02-12 | 아스트라제네카 아베 | 면역-조정 특성의 이미다조퀴놀린 |
| CA2691444C (en) | 2007-06-29 | 2016-06-14 | Gilead Sciences, Inc. | Purine derivatives and their use as modulators of toll-like receptor 7 |
| PE20091236A1 (es) | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
| JP2011530562A (ja) | 2008-08-11 | 2011-12-22 | グラクソスミスクライン エルエルシー | アレルギー性、炎症性及び感染性疾患治療用のプリン誘導体 |
| UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
| SI2320905T1 (sl) | 2008-08-11 | 2017-10-30 | Glaxosmithkline Llc Corporation Service Company | Novi adeninski derivati |
| ES2656813T3 (es) | 2008-10-24 | 2018-02-28 | Glaxosmithkline Biologicals Sa | Derivados de imidazoquinolina lipidados |
| ES2467108T3 (es) | 2008-12-09 | 2014-06-11 | Gilead Sciences, Inc. | Moduladores de receptores tipo toll |
| JP5206513B2 (ja) | 2009-03-12 | 2013-06-12 | オムロンヘルスケア株式会社 | 機能追加モジュール |
| CN102482233A (zh) | 2009-05-21 | 2012-05-30 | 阿斯利康(瑞典)有限公司 | 新颖的嘧啶衍生物和它们在治疗癌症和其它疾病中的用途 |
| WO2012067269A1 (en) | 2010-11-19 | 2012-05-24 | Dainippon Sumitomo Pharma Co., Ltd. | Aminoalkoxyphenyl compounds and their use in the treatment of disease |
| US20130267532A1 (en) | 2010-11-19 | 2013-10-10 | Shinya Tosaki | Cyclic amide compounds and their use in the treatment of disease |
| WO2012066335A1 (en) | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Phenol compounds als toll -like receptor 7 agonists |
| WO2012066336A1 (en) | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Benzylamine compounds as toll -like receptor 7 agonists |
| HUE055286T2 (hu) | 2011-04-08 | 2021-11-29 | Janssen Sciences Ireland Unlimited Co | Pirimidinszármazékok vírusfertõzések kezelésére |
| SG194852A1 (en) | 2011-05-18 | 2013-12-30 | Janssen R & D Ireland | Quinazoline derivatives for the treatment of viral infections and further diseases |
| TWI619704B (zh) | 2012-05-18 | 2018-04-01 | 大日本住友製藥股份有限公司 | 羧酸化合物 |
| EP2925729B1 (en) | 2012-11-16 | 2017-10-18 | Janssen Sciences Ireland UC | Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections |
| WO2014187878A1 (en) | 2013-05-21 | 2014-11-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Internal dna standards for assays using micro-electrophoresis |
| SG11201802832UA (en) | 2015-10-07 | 2018-05-30 | Sumitomo Dainippon Pharma Co Ltd | Pyrimidine compound |
| PL3603619T3 (pl) | 2017-03-29 | 2025-11-17 | Sumitomo Pharma Co., Ltd. | Preparat adjuwantu szczepionkowego |
-
2018
- 2018-03-28 PL PL18774978.3T patent/PL3603619T3/pl unknown
- 2018-03-28 WO PCT/JP2018/012637 patent/WO2018181420A1/ja not_active Ceased
- 2018-03-28 US US16/498,260 patent/US11253476B2/en active Active
- 2018-03-28 HU HUE18774978A patent/HUE073137T2/hu unknown
- 2018-03-28 CA CA3057813A patent/CA3057813A1/en active Pending
- 2018-03-28 JP JP2019509942A patent/JP7169968B2/ja active Active
- 2018-03-28 CN CN201880034048.0A patent/CN110650729B/zh active Active
- 2018-03-28 DK DK18774978.3T patent/DK3603619T3/da active
- 2018-03-28 ES ES18774978T patent/ES3039485T3/es active Active
- 2018-03-28 EP EP18774978.3A patent/EP3603619B1/en active Active
- 2018-03-28 FI FIEP18774978.3T patent/FI3603619T3/fi active
-
2022
- 2022-01-07 US US17/570,635 patent/US11833247B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11833247B2 (en) | 2023-12-05 |
| CA3057813A1 (en) | 2018-10-04 |
| CN110650729A (zh) | 2020-01-03 |
| US11253476B2 (en) | 2022-02-22 |
| US20220273563A1 (en) | 2022-09-01 |
| FI3603619T3 (fi) | 2025-09-25 |
| DK3603619T3 (da) | 2025-11-17 |
| JPWO2018181420A1 (ja) | 2020-02-06 |
| US20200121600A1 (en) | 2020-04-23 |
| HUE073137T2 (hu) | 2025-12-28 |
| EP3603619B1 (en) | 2025-08-13 |
| EP3603619A4 (en) | 2020-12-09 |
| JP7169968B2 (ja) | 2022-11-11 |
| WO2018181420A1 (ja) | 2018-10-04 |
| CN110650729B (zh) | 2024-08-20 |
| EP3603619A1 (en) | 2020-02-05 |
| ES3039485T3 (en) | 2025-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3603619T3 (pl) | Preparat adjuwantu szczepionkowego | |
| ZA201801035B (en) | Vaccine compositions | |
| GB201518684D0 (en) | Vaccine | |
| IL263624B (en) | HIV vaccine formulation | |
| EP3131579A4 (en) | Vaccine adjuvant compositions | |
| ZA201608487B (en) | Dual adjuvant vaccine compositions, preparation and uses | |
| SG11202105787QA (en) | Preparation including vaccine adjuvant | |
| GB201701239D0 (en) | Novel formulation | |
| GB201522132D0 (en) | Vaccine | |
| SG11202009147UA (en) | Vaccine compositions | |
| GB201704417D0 (en) | Improved li vaccine adjuvant | |
| GB2562241B (en) | Vaccine compositions | |
| GB201616904D0 (en) | Vaccine | |
| GB201608821D0 (en) | Vaccines | |
| IL258700A (en) | An excipient and a vaccine that includes it | |
| GB201811382D0 (en) | Vaccine | |
| GB201703529D0 (en) | Vaccine composition | |
| PT3297666T (pt) | Adjuvante e vacina molecular | |
| GB201718251D0 (en) | Vaccine Compositions | |
| GB201603029D0 (en) | Vaccine | |
| GB2564901B (en) | Vaccine compositions | |
| GB201712904D0 (en) | Vaccine | |
| HK40036700A (en) | Vaccine | |
| GB201704126D0 (en) | Vaccine | |
| GB201703809D0 (en) | Vaccine |